% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Telli:300101,
      author       = {T. Telli$^*$ and L. Lopes and M. Karpinski$^*$ and K. M.
                      Pabst$^*$ and V. Grünwald$^*$ and K. Shi and B.
                      Hadaschik$^*$ and C. Kesch$^*$ and L. Umutlu$^*$ and K.
                      Herrmann$^*$ and R. Seifert$^*$ and W. P. Fendler$^*$},
      title        = {{P}rognostic value of [18{F}]{FDG}- and {PSMA}-{PET} in
                      patients evaluated for [177{L}u]{L}u-{PSMA} therapy of
                      m{CRPC}.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {52},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2025-00601},
      pages        = {3199–3210},
      year         = {2025},
      note         = {Volume 52, pages 3199–3210, (2025)},
      abstract     = {To improve [177Lu]Lu-Prostate-specific membrane antigen
                      therapy (LuPSMA) selection, this study investigates the
                      prognostic value of PSMA and 2-[18F]fluoro-2-deoxy-D-glucose
                      ([18F]FDG)-PET in metastatic castration-resistant prostate
                      cancer (mCRPC) patients considered for LuPSMA therapy.We
                      conducted a retrospective analysis in 152 mCRPC patients
                      referred for LuPSMA therapy who underwent PSMA and
                      [18F]FDG-PET/CT. Of these, 104 patients $(68.4\%)$ underwent
                      LuPSMA therapy, while 48 $(31.6\%)$ received other standard
                      of care (SOC). PET/CT analyses included visual assessment
                      and semiquantitative measurements. Clinical and laboratory
                      parameters were recorded. Overall survival (OS) and PSA
                      response (decline > $50\%)$ were primary and secondary
                      endpoints, respectively.Baseline [18F]FDG-derived total
                      tumor volume was the only independent predictor of overall
                      survival both in patients subsequently treated with LuPSMA
                      (HR 1.28 $[95\%CI$ 1.02-1.61]; p = 0.03) or in those under
                      other SOC (HR 1.61 $[95\%CI$ 1.02-2.56]; p = 0.04),
                      respectively. In other SOC patients, additional independent
                      predictors of OS were total lesion PSMA uptake (PSMA-TL; HR
                      1.14 $[95\%CI$ 1.03-1.26]; p = 0.01), [18F]FDG mean SUV (HR
                      20.88 $[95\%CI$ 1.2-364.74]; p = 0.04), and [18F]FDG total
                      lesion glycolysis (HR 1.61 $[95\%CI$ 1.02-2.56]; p = 0.04).
                      In LuPSMA patients, PSMA-PET SUVmean was a significant
                      independent predictor of PSA decline ≥ $50\%$ (OR 2.97
                      $[95\%CI$ 1.27-8.16]; p = 0.02).PSMA-PET and [18F]FDG-PET
                      provide imaging biomarkers of outcome in candidates for
                      LuPSMA. FDG-PET total tumor volume was an independent
                      predictor of overall survival in candidates for LuPSMA
                      therapy, irrespective of subsequent treatment decision.
                      PSMA-PET SUVmean was associated with biochemical response to
                      LuPSMA. Dual tracer imaging should further be assessed in
                      prospective trials for mCRPC treatment guidance.},
      keywords     = {Biomarkers (Other) / FDG (Other) / PSMA (Other) /
                      Prognostics (Other) / Prostate cancer (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40113645},
      doi          = {10.1007/s00259-025-07198-y},
      url          = {https://inrepo02.dkfz.de/record/300101},
}